DouglasWestonSborovMD

PubMed

• 1 citations
  Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/ refractory multiple myeloma: US Myeloma Immunothera...
  Castaneda Puglianini, O., Hamza Hashmi, Doris K Hansen, Lauren C Peres, Omar Castaneda Puglianini, Ciara Freeman, Gabriel De Avila, Surbhi Sidana, Leyla Shune, Douglas...> ;Haematologica. 2024 May 1
• Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk.
  Natalie S Callander, Rebecca Silbermann, Jonathan L Kaufman, Kelly N Godby, Jacob Laubach, Timothy M Schmidt, Douglas W Sborov, Eva Medvedova, Brandi Reeves, Binod Dha...> ;Blood Cancer Journal. 2024 Apr 22
• Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethas...
  Rebecca Silbermann, Jacob Laubach, Jonathan L Kaufman, Douglas W Sborov, Brandi Reeves, Cesar Rodriguez, Ajai Chari, Luciano J Costa, Larry D Anderson Jr, Nitya Nathwa...> ;American Journal of Hematology. 2024 Apr 15
• Sequence not salvage.
  Gliceida Galarza Fortuna, Patrick J Hayden, Douglas W Sborov> ;British Journal of Haematology. 2024 May 1
• 1 citations
  Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review.
  Karun Neupane, Gliceida Galarza Fortuna, Riyasha Dahal, Timothy Schmidt, Rafael Fonseca, Rajshekhar Chakraborty, Kelly Ann Koehn, Meera Mohan, Hira Mian, Luciano J Cos...> ;Blood Cancer Journal. 2024 Jan 25
• Patient perspectives on BCMA-targeted therapies for multiple myeloma: a survey conducted in a patient advocacy group.
  Jay R Hydren, Dee Lin, Nathan W Sweeney, Bingcao Wu, Nina Kim, Saurabh Patel, Douglas W Sborov, Jesus G Berdeja, Larry D Anderson Jr, Stephen Huo, Jorge Arturo Hurtado...> ;Frontiers in Health Services. 2024 Jan 1
• Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
  Shaji K Kumar, Natalie S Callander, Kehinde Adekola, Larry D Anderson Jr, Muhamed Baljevic, Rachid Baz, Erica Campagnaro, Jorge J Castillo, Caitlin Costello, Christoph...> ;Journal of the National Comprehensive Cancer Network. 2024 Jan 1
• 4 citations
  Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
  Shaji K Kumar, Natalie S Callander, Kehinde Adekola, Larry D Anderson Jr, Muhamed Baljevic, Rachid Baz, Erica Campagnaro, Jorge J Castillo, Caitlin Costello, Christoph...> ;Journal of the National Comprehensive Cancer Network. 2023 Dec 1
• Obinutuzumab-Based Drug-Free Macromolecular Therapeutics Synergizes with Topoisomerase Inhibitors.
  M Tommy Gambles, Douglas Sborov, Paul Shami, Jiyuan Yang, Jindřich Kopeček> ;Macromolecular Bioscience. 2024 Mar 1
• Correction: HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide.
  Alessandro Canella, Hector Cordero Nieves, Douglas W Sborov, Luciano Cascione, Hanna S Radomska, Emily Smith, Andrew Stiff, Jessica Consiglio, Enrico Caserta, Lara Riz...> ;Oncotarget. 2023 Sep 25
• 4 citations
  Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment.
  Surbhi Sidana, Lauren C Peres, Hamza Hashmi, Hitomi Hosoya, Christopher Ferreri, Jack Khouri, Danai Dima, Shebli Atrash, Peter Voorhees, Gary Simmons, Douglas W Sborov...> ;Haematologica. 2024 Mar 1
• Correction: Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes.
  Sonja I Berndt, Joseph Vijai, Yolanda Benavente, Nicola J Camp, Alexandra Nieters, Zhaoming Wang, Karin E Smedby, Geffen Kleinstern, Henrik Hjalgrim, Caroline Besson, ...> ;Leukemia. 2023 Oct 1
• 3 citations
  Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial.
  Ajay K Nooka, Adam D Cohen, Hans C Lee, Ashraf Badros, Attaya Suvannasankha, Natalie Callander, Al-Ola Abdallah, Suzanne Trudel, Ajai Chari, Edward N Libby, Maria Chau...> ;Cancer. 2023 Dec 1
• Understanding risks and refining strategies for thromboembolism prophylaxis in hematopoietic stem cell transplant recipients.
  Muhamed Baljevic, Douglas W Sborov> ;Bone Marrow Transplantation. 2023 Nov 1
• 16 citations
  Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy.
  Castaneda Puglianini, O., Christopher J Ferreri, Michelle A T Hildebrandt, Hamza Hashmi, Leyla O Shune, Joseph P McGuirk, Douglas W Sborov, Charlotte B Wagner, M Hakan...> ;Blood Cancer Journal. 2023 Aug 9
• Attrition and withdrawal in multiple myeloma randomized controlled trials: A systematic review.
  Stijn Hentzen, Tomer Meirson, Kelly Koehn, Aaron Goodman, Rajshekhar Chakraborty, Douglas Sborov, Samuel Rubinstein, Ghulam Rehman Mohyuddin> ;European Journal of Haematology. 2023 Sep 1
• Refractoriness to last line of therapy: how often is it mandated and reported? A systematic review of randomized myeloma trials.
  Poorva Bindal, Mimi Najjar, Kelly Koehn, Amandeep Godara, Douglas W Sborov, Brian McClune, Kelley Julian, Charlotte Wagner, Ghulam Rehman Mohyuddin> ;Leukemia & Lymphoma. 2023 May 11
• The Landscape of Currently Enrolling Maintenance Trials in Multiple Myeloma.
  Syed Maaz Tariq, Al-Ola Abdallah, Aaron Goodman, Douglas Sborov, Ghulam Rehman Mohyuddin, Britt, A., Alec Britt> ;Clinical Hematology International. 2023 Jun 1
• 19 citations
  Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial.
  Zachary D Crees, Michael P Rettig, Reyka G Jayasinghe, Keith Stockerl-Goldstein, Sarah M Larson, Illes Arpad, Giulio A Milone, Massimo Martino, Patrick Stiff, Douglas ...> ;Nature Medicine. 2023 Apr 1
• 4 citations
  Time-to-event surrogate end-points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis.
  Tommy Etekal, Kelly Koehn, Douglas W Sborov, Brian McClune, Vinay Prasad, Alyson Haslam, Katherine Berger, Christopher Booth, Samer Al Hadidi, Al-Ola Abdallah, Aaron G...> ;British Journal of Haematology. 2023 Mar 1
• Deep Transcriptome Profiling of Multiple Myeloma Using Quantitative Phenotypes.
  Rosalie Griffin, Heidi A Hanson, Brian J Avery, Michael J Madsen, Douglas W Sborov, Nicola J Camp> ;Cancer Epidemiology, Biomarkers & Prevention. 2023 May 1
• 6 citations
  A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma.
  Barry Paul, Michaela Liedtke, Jack Khouri, Robert Rifkin, Mitul D Gandhi, Andrew Kin, Moshe Y Levy, Rebecca Silbermann, Francesca Cottini, Douglas W Sborov, Irwindeep ...> ;Future Oncology. 2023 Jan 1
• 57 citations
  Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium.
  Doris K Hansen, Surbhi Sidana, Lauren C Peres, Christelle Colin Leitzinger, Leyla Shune, Alexandria Shrewsbury, Rebecca Gonzalez, Douglas W Sborov, Charlotte Wagner, D...> ;Journal of Clinical Oncology. 2023 Apr 10
• Allogeneic stem cell transplant for multiple myeloma & myelofibrosis with split-dose busulfan, fludarabine & cyclophosphamide.
  Andrew D Trunk, Sagar S Patel, Josef T Prchal, Douglas W Sborov, Axel R Zander, Catherine J Lee> ;Leukemia Research Reports. 2023 Jan 1
• 6 citations
  Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.
  Shaji K Kumar, Natalie S Callander, Kehinde Adekola, Larry D Anderson Jr, Muhamed Baljevic, Erica Campagnaro, Jorge J Castillo, Caitlin Costello, Christopher D'Angelo,...> ;Journal of the National Comprehensive Cancer Network. 2023 Jan 1
• Join now to see all

Abstracts/Posters

• Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnose...
  Douglas W. Sborov, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Proteasome Inhibitors Impair the Innate Antiviral Immune Response and Potentiate Pelareorep-Based Viral Therapy in Multiple Myeloma
  Douglas W. Sborov, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

• Lenalidomide and Vorinostat Maintenance after Autologous Transplant in Multiple Myeloma- Long Term Follow-up 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018